Protective role of cortistatin in pulmonary inflammation and fibrosis.

Margarita BarrigaRaquel BenitezViviane Ferraz-de-PaulaMarina Garcia-FrutosMarta CaroGema RobledoFrancisco O'ValleJenny Campos-SalinasMario Delgado

Published in: British journal of pharmacology (2021)

We identified cortistatin as an endogenous inhibitor of pulmonary inflammation and fibrosis. Deficiency in cortistatin could be a marker of poor prognosis in inflammatory/fibrotic pulmonary disorders. Cortistatin-based therapies could emerge as attractive candidates to treat severe ALI/ARDS, including SARS-CoV-2-associated ARDS.

Keyphrases

poor prognosis
pulmonary hypertension
oxidative stress
sars cov
long non coding rna
acute respiratory distress syndrome
extracorporeal membrane oxygenation
mechanical ventilation
idiopathic pulmonary fibrosis
early onset
respiratory syndrome coronavirus
intensive care unit
liver fibrosis